Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Okays Liquidia’s YUTREPIA Inhalation for PAH and PH-ILD Patients
Details : Yutrepia is an FDA-approved, inhaled dry-powder formulation of treprostinil indicated for the treatment of pulmonary hypertension.
Product Name : Yutrepia
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 23, 2025
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : Pharmosa Biopharm
Deal Size : $161.2 million
Deal Type : Expanded Collaboration
Pharmosa Biopharm Expands Liquida Collaboration for Smart Nebulizers
Details : The agreement aims for the development and commercialization of L606, an inhaled, sustained-release formulation of treprostinil being evaluated for the treatment of PAH and PH-ILD.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $3.5 million
October 04, 2024
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : Pharmosa Biopharm
Deal Size : $161.2 million
Deal Type : Expanded Collaboration
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : Pharmosa Biopharm
Deal Size : $225.0 million
Deal Type : Collaboration
Details : Liquidia will be responsible for development, regulatory and commercial activities of L606, an inhaled, sustained-release formulation of treprostinil being evaluated for treating PAH and pulmonary hypertension associated with interstitial lung disease, i...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $10.0 million
June 28, 2023
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : Pharmosa Biopharm
Deal Size : $225.0 million
Deal Type : Collaboration
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : HealthCare Royalty Partners
Deal Size : $100.0 million
Deal Type : Financing
Details : Liquidia intends to use the proceeds to fund the potential launch of Yutrepia, an inhaled dry powder formulation of treprostinil, upon final regulatory approval by the U.S. FDA and to support the continued clinical development of Yutrepia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 09, 2023
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : HealthCare Royalty Partners
Deal Size : $100.0 million
Deal Type : Financing
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : United Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent
Details : YUTREPIA/Tyvaso (treprostinil) inhalation powder, is an investigational, inhaled dry powder formulation of treprostinil delivered through a proven, convenient, palm-sized device for the treatment of pulmonary arterial hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 19, 2022
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : United Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Tentative Approval for Liquidia’s YUTREPIA™ (Treprostinil) Inhalation Powder
Details : YUTREPIA is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability in adult patients. Tentative approval indicates that YUTREPIA has met all regulatory standards required for approval.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 08, 2021
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LIQ861 (treprostinil) Inhalation Powder and act as platelet aggregation, which being evaluated for the treatment of patients with pulmonary arterial hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 10, 2021
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : PPD
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
Details : L606 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Arterial Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 31, 2020
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : PPD
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The patent is expected to cover methods of treating patients with pulmonary hypertension through the inhalation of dry powder treprostinil.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2020
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New data from INSPIRE LIQ861 safety and tolerability study in pulmonary arterial hypertension (PAH) patients demonstrate positive trends in exploratory endpoints, including quality of life (QoL)
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 05, 2020
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable